Entries by scorch20

QR Pharma, Inc. Presents New Data on Posiphen in Alzheimer’s and Parkinson’s Disease at the 13th AD/PD International Conference

–Posiphen Restores Memory and Learning and Brain Function as well as Gut Motility and Coordination in Mice Models of AD and PD–   Berwyn, Pa., March 16, 2017 — QR Pharma, Inc., a privately held phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s (AD), Parkinson’s (PD) and other neurodegenerative diseases, today announced […]

QR Pharma Announces New Scientific Advisory Board with Appointment of World-Class Neurodegenerative Disease Experts

Four Neurology Experts Join Advisory Board Following Recent Breakthrough Discoveries Regarding Posiphen Mechanism of Action Berwyn, PA, January 24, 2017 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced the appointment of four world-class key opinion leaders to  its […]

QR Pharma Raises $800,000 of Series A Preferred Stock

Berwyn, PA., October 27, 2016 — QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, has closed on $800,000 of Series A Preferred Stock financing. Existing investors Robin Hood Ventures and individual angels filled this round. QR Pharma will use the funding to continue […]

QR Pharma, Inc. to Participate in Harvard’s Neuro Advance Boston Conference

–President and CEO, Dr. Maria Maccecchini, to Speak in Panel–   Berwyn, Pa., October 4, 2016 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., President and CEO, will participate in the Neuro Advance Boston […]

New Data on Posiphen in Traumatic Brain Injury

QR Pharma, Inc. Presents New Data on Posiphen in Traumatic Brain Injury at 2016 Military Health System Research Symposium –Posiphen Reverses Behavioral Deficits and Neuropathology Caused by Traumatic Brain Injury– Berwyn, Pa., August 17, 2016 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and […]